Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 5
1983 2
1985 1
1987 1
1988 1
1989 5
1990 1
1991 4
1992 8
1993 5
1994 8
1995 6
1996 7
1997 5
1998 8
1999 9
2000 8
2001 5
2002 11
2003 9
2004 5
2005 7
2006 15
2007 13
2008 11
2009 4
2010 5
2011 6
2012 4
2013 10
2014 2
2015 13
2016 12
2017 13
2018 16
2019 15
2020 15
2021 15
2022 17
2023 10
2024 8
2025 10
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. Nevens F, et al. Among authors: floreani a. N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840. N Engl J Med. 2016. PMID: 27532829 Free article. Clinical Trial.
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE; Global PBC Study Group. Lammers WJ, et al. Among authors: floreani a. Gastroenterology. 2014 Dec;147(6):1338-49.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029. Epub 2014 Aug 23. Gastroenterology. 2014. PMID: 25160979
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ. Harms MH, et al. Among authors: floreani a. J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11. J Hepatol. 2019. PMID: 30980847
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Murillo Perez CF, et al. Among authors: floreani a. Am J Gastroenterol. 2020 Jul;115(7):1066-1074. doi: 10.14309/ajg.0000000000000557. Am J Gastroenterol. 2020. PMID: 32618657
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F; Global & ERN Rare-Liver PBC Study Groups. Corpechot C, et al. Among authors: floreani a. Hepatology. 2024 Jan 1;79(1):39-48. doi: 10.1097/HEP.0000000000000529. Epub 2023 Jul 3. Hepatology. 2024. PMID: 37399238
Etiopathogenesis of autoimmune hepatitis.
Floreani A, Restrepo-Jiménez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, Bowlus CL, Gershwin ME, Anaya JM. Floreani A, et al. J Autoimmun. 2018 Dec;95:133-143. doi: 10.1016/j.jaut.2018.10.020. Epub 2018 Oct 29. J Autoimmun. 2018. PMID: 30385083 Review.
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.
Lam L, Soret PA, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Parés A, Olivas I, Londono MC, Rodríguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédinghen V, Carrat F, Chazouillères O, Corpechot C; Global & ERN Rare-Liver PBC Study Groups. Lam L, et al. Among authors: floreani a. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2432-2441.e2. doi: 10.1016/j.cgh.2024.06.035. Epub 2024 Jul 15. Clin Gastroenterol Hepatol. 2024. PMID: 39019421 Free article.
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
Wong YJ, Lam L, Soret PA, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, Lytvyak E, Pares A, Olivas I, Londono MC, Rogriguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédinghen V, Carrat F, Chazouillères O, Corpechot C, Montano-Loza AJ; Global & ERN Rare-Liver PBC Study Groups. Wong YJ, et al. Among authors: floreani a. J Hepatol. 2026 Feb;84(2):275-283. doi: 10.1016/j.jhep.2025.09.024. Epub 2025 Oct 3. J Hepatol. 2026. PMID: 41047080 Free article.
Treatment of primary sclerosing cholangitis.
Floreani A, De Martin S. Floreani A, et al. Dig Liver Dis. 2021 Dec;53(12):1531-1538. doi: 10.1016/j.dld.2021.04.028. Epub 2021 May 16. Dig Liver Dis. 2021. PMID: 34011480 Review.
Primary biliary cholangitis: treatment.
Cazzagon N, Floreani A. Cazzagon N, et al. Among authors: floreani a. Curr Opin Gastroenterol. 2021 Mar 1;37(2):99-104. doi: 10.1097/MOG.0000000000000708. Curr Opin Gastroenterol. 2021. PMID: 33492001 Review.
310 results